AI Enabled Drug Discovery with Daphne Koller ODSC's Ai X Podcast
-
- Technology
This interview was recorded and previously published in April of 2023. With the resurgence of AI in the news and recent advancements in the use of LLMs for biotech, we thought it would be a good time to revisit this engaging and informative interview.
Speaker Bio:
Daphne Koller is a trailblazer in the fields of AI, machine learning, education, and biology, as well as a visionary and inspiring entrepreneur.
Daphne Koller is CEO and Founder of insitro, a machine learning-driven drug discovery and development company, and co-founder of Engageli. She has authored over 300 referred publications with an h-index of 146 and was recognized as one of TIME Magazine’s 100 most influential people in 2012.
Sponsored by: https://odsc.com/
Find more ODSC lightning interviews, webinars, live trainings, certifications, bootcamps here – https://aiplus.training/
Podcast Topics
1. Tell us about your journey to becoming one of the foremost experts at the intersection of biology and AI and what motivated you to pursue expertise in both fields.
2. How would you describe the core mission and goals of Insitro?
3. Can you explain the key differences between traditional drug discovery approaches and Insitro's AI-driven methodology?
4. Why is the failure rate of drug development so high?
5. What are the main challenges in integrating AI with experimental biology, and how did you and your team address these challenges?
6. In your opinion, what are the most significant advancements in AI that have impacted or have the potential to impact biological research?
7. Can you share another example of a biological problem or research question that has been successfully addressed using AI techniques, by you, your team, or others?
8. How do AI researchers in this field generate the large-scale, high-quality biological data needed for their AI models?
9. What are the most important lessons you have learned as a founder and leader in the AI-driven biotechnology space?
10. Considering the growing integration of AI in biology and drug discovery, what measures should be taken to ensure AI is safely used in this space? Is it possible to address potential risks and unintended consequences that may arise from AI-driven biological research?
11. How do you see the potential of generative models for enhancing drug discovery, and what are the key challenges and opportunities in applying these models?
12. What are your thoughts on the current state of AI regulation, and what measures or policies should be implemented to ensure responsible and ethical development and deployment of AI technologies? What's your take on the “Pause AI” letter?
13 How have the recent advancements in large language models (LLMs) and generative AI changed your perspective on the potential and limitations of AI across various industries and applications?
14. If you could choose any superpower to assist you in your work, what would it be and why?
15. What will be the subject of your keynote speech at ODSC East in a few weeks?
16. What is the best medium for people to follow your work?
This interview was recorded and previously published in April of 2023. With the resurgence of AI in the news and recent advancements in the use of LLMs for biotech, we thought it would be a good time to revisit this engaging and informative interview.
Speaker Bio:
Daphne Koller is a trailblazer in the fields of AI, machine learning, education, and biology, as well as a visionary and inspiring entrepreneur.
Daphne Koller is CEO and Founder of insitro, a machine learning-driven drug discovery and development company, and co-founder of Engageli. She has authored over 300 referred publications with an h-index of 146 and was recognized as one of TIME Magazine’s 100 most influential people in 2012.
Sponsored by: https://odsc.com/
Find more ODSC lightning interviews, webinars, live trainings, certifications, bootcamps here – https://aiplus.training/
Podcast Topics
1. Tell us about your journey to becoming one of the foremost experts at the intersection of biology and AI and what motivated you to pursue expertise in both fields.
2. How would you describe the core mission and goals of Insitro?
3. Can you explain the key differences between traditional drug discovery approaches and Insitro's AI-driven methodology?
4. Why is the failure rate of drug development so high?
5. What are the main challenges in integrating AI with experimental biology, and how did you and your team address these challenges?
6. In your opinion, what are the most significant advancements in AI that have impacted or have the potential to impact biological research?
7. Can you share another example of a biological problem or research question that has been successfully addressed using AI techniques, by you, your team, or others?
8. How do AI researchers in this field generate the large-scale, high-quality biological data needed for their AI models?
9. What are the most important lessons you have learned as a founder and leader in the AI-driven biotechnology space?
10. Considering the growing integration of AI in biology and drug discovery, what measures should be taken to ensure AI is safely used in this space? Is it possible to address potential risks and unintended consequences that may arise from AI-driven biological research?
11. How do you see the potential of generative models for enhancing drug discovery, and what are the key challenges and opportunities in applying these models?
12. What are your thoughts on the current state of AI regulation, and what measures or policies should be implemented to ensure responsible and ethical development and deployment of AI technologies? What's your take on the “Pause AI” letter?
13 How have the recent advancements in large language models (LLMs) and generative AI changed your perspective on the potential and limitations of AI across various industries and applications?
14. If you could choose any superpower to assist you in your work, what would it be and why?
15. What will be the subject of your keynote speech at ODSC East in a few weeks?
16. What is the best medium for people to follow your work?